English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The effect of  Alstonia boonei  fractions on glucose homeostasis was investigated via  in vitro  enzyme inhibition activity,  ex vivo  glucose uptake assay, and  in vivo  methods in diabetic rats. A. boonei  fractions were subjected to  in vitro  α-glucosidase inhibitory assay and then  ex vivo  glucose uptake activity. The butanol fraction of the leaves (ABBF) was picked for the  in vivo  assay since it showed more activity in the initial tests conducted. ABBF was administrated via oral dosing to six-weeks old fructose-fed STZ-induced type 2 diabetic rats over a 5-week experimental period. ABBF treatment at a low dose of 150 mg/kg bw, significantly ( p  &lt; .05) reduced blood glucose level, enhanced oral glucose tolerance ability, restored insulin secretion and hepatic glycogen synthesis as well as promoted islet regeneration than the high dose (300 mg/kg bw). These results suggest that ABBF could be exploited as a therapeutic potential for treating T2D.

Butanol fraction of Alstonia boonei De Wild. leaves ameliorate oxidative stress and modulate key hypoglycaemic processes in diabetic rats